Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: Case report and review of literature

Liver International

Volumn 26, Issue 5, 2006, Pages 625-629

  Santos, Edgardo S ^a   Arosemena, Leopoldo R ^b   Raez, Luis E ^b   O'Brien, Christopher ^b   Regev, Arie ^b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune hepatitis; Idiopathic thrombocytopenic purpura; Monoclonal antibody; Rituximab

Indexed keywords

AMINOTRANSFERASE; DANAZOL; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ARTICLE; AUTOIMMUNE HEPATITIS; BIOCHEMISTRY; CASE REPORT; CLINICAL FEATURE; CLINICAL STUDY; DRUG DOSE REGIMEN; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LABORATORY TEST; THROMBOCYTE COUNT; TREATMENT OUTCOME; VALIDATION PROCESS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER FUNCTION TESTS; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TREATMENT OUTCOME;

EID: 33646809309     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01262.x     Document Type: Article

References (26)

1. Czaja A J, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988; 95: 448-53.
2. Czaja A J, Freese D K. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479-97.
3. Tranchida P, Bayerl M, Voelpel M J, et al. Testicular ichemia due to intravascular large B-cell lymphomas: A novel presentation in an immunosuppressed individual. Int J Surg Pathol 2003; 11: 319-24.
4. Zugmaier G, Jager R, Neubauer A, et al. Fatal bleeding complications caused by Evans syndrome (autoimmune thrombocytopenia and hemolytic anemia) and type II autoimmune hepatitis in a 56-year-old patient. Med Klin 2002; 97: 88-90.
5. Yamaike N, Saigo K, Imoto S, et al. Autoimmune hepatitis accompanied by idiopathic thrombocytopenic purpura and Sjogren's syndrome. Int Med 2002; 41: 72.
6. Arakawa Y, Amaki S, Miyakawa H, et al. PBC-AIH overlap syndrome with concomitant ITP and Hashimoto's disease with positivity for anti-centromere antibody. J Gastroenterol 2004; 39: 490-5.
7. Koulova L, Alexandrescu D, Dutcher J P, et al. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): Report of three cases. Am J Hematol 2005; 78: 49-54.
8. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004; 125: 232-9.
9. Alvarez F, Berg P A, Bianchi F B, et al. International autoimmune hepatitis group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
10. Mcfarlane I G. Autoimmune hepatitis: Diagnostic criteria, subclassifications, and clinical features. Clin Liver Dis 2002; 6: 317-33.
11. Vergani D, Choudhuri K, Bogadnos D P, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002; 6: 439-49.
12. Czaja A J. Treatment strategies in autoimmune hepatitis. Clin Liver Dis 2002; 6: 799-824.
13. Den Ottolander G J, Gratama J W, De Koning J, et al. Long-term follow-up study of 168 patients with immune thrombocytopenia: Implications for therapy. Scand J Haematol 1984; 32: 101-10.
14. Difino S M, Lachant N A, Kirshner J J, et al. Adult idiopathic thrombocytopenic purpura: Clinical findings and response to therapy. Am J Med 1980; 69: 430-42.
15. Newman G C, Novoa M V, Fodero E M, et al. A dose of 75 ug/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 ug/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 2001; 112: 1076-8.
16. Bussel J B, Pham L C. Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: Review of the literature. Vox Sang 1987; 52: 206-11.
17. Lalayanni C, Stavroyianni N, Saloum R, et al. Rituximab is effective for selected patients with chronic steroid-refractory immune thrombocytopenic purpura. Hematology 2004; 9: 287-9.
18. Silverman G J, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003; 48: 1484-92.
19. Maloney D G, Smith B, Rose A. Rituximab: Mechanism of action and resistance. Semin Oncol 2002; 29 (Suppl. 2): 2-9.
20. Abrahams V M, Cambridge G, Lydyard P M, et al. Induction of tumor necrosis factor alpha production by adhered human monocytes: A key role for Fcgamma receptor type IIIa in rheumatoid arthritis. Arthritis Rheum 2000; 43: 608-16.
21. Dijstelbloem H M, Van De Winkel J G, Kallenberg C G. Inflammation in autoimmunity: Receptors for IgG revisited. Trends Immunol 2001; 22: 510-6.
22. De Vita S, Zaja F, Sacco S, et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cell. Arthritis Rheum 2002; 46: 2029-33.
23. Leandro M J, Edwards J C, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61: 883-8.
24. Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003; 74: 485-9.
25. Anolik J, Sanz I, Looney R J. B cell depletion therapy in systemic lupus erythematous. Curr Rheumatol Rep 2003; 5: 350-6.
26. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-34.